Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters











Database
Language
Publication year range
1.
Neurology ; 100(17): e1812-e1824, 2023 04 25.
Article in English | MEDLINE | ID: mdl-36882326

ABSTRACT

BACKGROUND AND OBJECTIVES: Small vessel disease (SVD) and neuroinflammation both occur in Alzheimer disease (AD) and other neurodegenerative diseases. It is unclear whether these processes are related or independent mechanisms in AD, especially in the early stages of disease. We therefore investigated the association between white matter lesions (WML; the most common manifestation of SVD) and CSF biomarkers of neuroinflammation and their effects on cognition in a population without dementia. METHODS: Individuals without dementia from the Swedish BioFINDER study were included. The CSF was analyzed for proinflammatory markers (interleukin [IL]-6 and IL-8), cytokines (IL-7, IL-15, and IL-16), chemokines (interferon γ-induced protein 10, monocyte chemoattractant protein 1), markers of vascular injury (soluble intercellular adhesion molecule 1, soluble vascular adhesion molecule 1), and markers of angiogenesis (placental growth factor [PlGF], soluble fms-related tyrosine kinase 1 [sFlt-1], vascular endothelial growth factors [VEGF-A and VEFG-D]), and amyloid ß (Aß)42 Aß40, and p-tau217. WML volumes were determined at baseline and longitudinally over 6 years. Cognition was measured at baseline and follow-up over 8 years. Linear regression models were used to test associations. RESULTS: A total of 495 cognitively unimpaired (CU) elderly individuals and 247 patients with mild cognitive impairment (MCI) were included. There was significant worsening in cognition over time, measured by Mini-Mental State Examination, Clinical Dementia Rating, and modified preclinical Alzheimer composite score in CU individuals and patients with MCI, with more rapid worsening in MCI for all cognitive tests. At baseline, higher levels of PlGF (ß = 0.156, p < 0.001), lower levels of sFlt-1 (ß = -0.086, p = 0.003), and higher levels of IL-8 (ß = 0.07, p = 0.030) were associated with more WML in CU individuals. In those with MCI, higher levels of PlGF (ß = 0.172, p = 0.001), IL-16 (ß = 0.125, p = 0.001), IL-8 (ß = 0.096, p = 0.013), IL-6 (ß = 0.088, p = 0.023), VEGF-A (ß = 0.068, p = 0.028), and VEGF-D (ß = 0.082, p = 0.028) were associated with more WML. PlGF was the only biomarker that was associated with WML independent of Aß status and cognitive impairment. Longitudinal analyses of cognition showed independent effects of CSF inflammatory markers and WML on longitudinal cognition, especially in people without cognitive impairment at baseline. DISCUSSION: Most neuroinflammatory CSF biomarkers were associated with WML in individuals without dementia. Our findings especially highlight a role for PlGF, which was associated with WML independent of Aß status and cognitive impairment.


Subject(s)
Alzheimer Disease , Cognitive Dysfunction , Vascular Diseases , White Matter , Aged , Female , Humans , Alzheimer Disease/complications , Amyloid beta-Peptides , Biomarkers , Cognitive Dysfunction/complications , Inflammation/complications , Interleukin-16 , Interleukin-8 , Neuroinflammatory Diseases , Placenta Growth Factor , tau Proteins , Vascular Diseases/complications , Vascular Endothelial Growth Factor A
2.
Neurology ; 96(2): e193-e202, 2021 01 12.
Article in English | MEDLINE | ID: mdl-33046608

ABSTRACT

OBJECTIVE: To investigate the relationship between enlarged perivascular spaces (EPVS) and measures of Alzheimer disease (AD), small vessel disease (SVD), cognition, vascular risk factors, and neuroinflammation, we tested associations between EPVS and different relevant neuroimaging, biochemical, and cognitive variables in 778 study participants. METHODS: Four hundred ninety-nine cognitively unimpaired (CU) individuals, 240 patients with mild cognitive impairment, and 39 patients with AD from the Swedish Biomarkers for Identifying Neurodegenerative Disorders Early and Reliably (BioFINDER) study were included. EPVS with diameter >1 mm in centrum semiovale (CSO), basal ganglia (BG), and hippocampus (HP); hippocampal volume; white matter lesions (WML); and other SVD markers were determined from MRI. CSF levels of ß-amyloid42 (Aß42), phosphorylated tau, total tau, and neuroinflammatory markers; amyloid accumulation determined with [18F]-flutemetamol PET; and vascular risk factors and results from cognitive tests were determined and collected. RESULTS: EPVS in CSO, BG, and HP were associated with WML volume and Fazekas score in individuals without dementia. No associations were found between EPVS and CSF Aß42, total tau and phosphorylated tau, neuroinflammatory markers, vascular risk factors, and cognitive tests. EPVS in HP were associated with hippocampal atrophy. In a matched group of individuals with AD and CU, EPVS in HP were associated with AD diagnosis. CONCLUSIONS: EPVS are related to SVD, also in early disease stages, but the lack of correlation with cognition suggests that their importance is limited. Our data do not support a role for EPVS in early AD pathogenesis.


Subject(s)
Alzheimer Disease/cerebrospinal fluid , Alzheimer Disease/diagnostic imaging , Cerebral Small Vessel Diseases/cerebrospinal fluid , Cerebral Small Vessel Diseases/diagnostic imaging , Glymphatic System/diagnostic imaging , Microvessels/diagnostic imaging , Aged , Alzheimer Disease/epidemiology , Biomarkers/cerebrospinal fluid , Cerebral Small Vessel Diseases/epidemiology , Cognitive Dysfunction/cerebrospinal fluid , Cognitive Dysfunction/diagnostic imaging , Cognitive Dysfunction/epidemiology , Female , Humans , Longitudinal Studies , Magnetic Resonance Imaging/methods , Male , Positron-Emission Tomography/methods , Prospective Studies , Sweden/epidemiology
3.
J Alzheimers Dis ; 54(3): 1027-1037, 2016 10 04.
Article in English | MEDLINE | ID: mdl-27567809

ABSTRACT

BACKGROUND: Volumetry of medial temporal lobe (MTL) structures to diagnose Alzheimer's disease (AD) in its earliest symptomatic stage could be of great importance for interventions or disease modifying pharmacotherapy. OBJECTIVE: This study aimed to demonstrate the first application of an automatic segmentation method of MTL subregions in a clinical population. Automatic segmentation of magnetic resonance images (MRIs) in a research population has previously been shown to detect evidence of neurodegeneration in MTL subregions and to help discriminate AD and mild cognitive impairment (MCI) from a healthy comparison group. METHODS: Clinical patients were selected and T2-weighted MRI scan quality was checked. An automatic segmentation method of hippocampal subfields (ASHS) was applied to scans of 67 AD patients, 38 amnestic MCI patients, and 57 healthy controls. Hippocampal subfields, entorhinal cortex (ERC), and perirhinal cortex were automatically labeled and subregion volumes were compared between groups. RESULTS: One fourth of all scans were excluded due to bad scan quality. There were significant volume reductions in all subregions, except BA36, in aMCIs (p < 0.001), most prominently in Cornu Ammonis 1 (CA1) and ERC, and in all subregions in AD. However, sensitivity of CA1 and ERC hardly differed from sensitivity of WH in aMCI and AD. CONCLUSION: Applying automatic segmentation of MTL subregions in a clinical setting as a potential biomarker for prodromal AD is feasible, but issues of image quality due to motion remain to be addressed. CA1 and ERC provided strongest group discrimination in differentiating aMCIs from controls, but discriminatory power of different subfields was low overall.


Subject(s)
Alzheimer Disease/diagnostic imaging , Cognitive Dysfunction/diagnostic imaging , Image Processing, Computer-Assisted/methods , Magnetic Resonance Imaging/methods , Prodromal Symptoms , Temporal Lobe/diagnostic imaging , Aged , Aged, 80 and over , Alzheimer Disease/psychology , Cognitive Dysfunction/psychology , Cohort Studies , Dementia/diagnostic imaging , Dementia/psychology , Female , Humans , Male , Middle Aged
SELECTION OF CITATIONS
SEARCH DETAIL